Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Thalidomide Celgene · 1 trial · 1 indication
PK blood sampling for a single day (on Day 5)
| Arm | Type | Description |
|---|---|---|
| Thalidomide Celgene™ 200mg once daily | EXPERIMENTAL | 5-day period of thalidomide treatment |
| Name | Type | Description |
|---|---|---|
| Thalidomide Celgene™ | DRUG | 200mg once daily and by mouth |
Inclusion Criteria: * Males and females ≥ at 18 the time of signing the informed consent document. * Documented diagnosis of multiple myeloma and receiving thalidomide containing therapy or initiating thalidomide-containing therapy. * Subjects must agree to temporally discontinue all antimyeloma th...
Top 20 of 25 competitors
Thalidomide Celgene is used in multiple myeloma, a cancer of plasma cells in the bone marrow. It is an oncology small molecule developed by Bristol-Myers Squibb Company under the ticker BMY. The program is in Phase 1 clinical development, so it remains investigational rather than an approved therapy.
Thalidomide Celgene targets CRBN, DDB1, CUL4A, and RBX1. It is classified as an inhibitor that acts on this protein complex. CRBN, or cereblon, is the primary binding partner, and the DDB1, CUL4A, and RBX1 components form the associated E3 ubiquitin ligase complex.
Thalidomide Celgene is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. Bristol-Myers Squibb is the sponsor of the clinical program for this oncology asset in multiple myeloma.
Thalidomide Celgene is in Phase 1 clinical development for multiple myeloma. It is an investigational small molecule and has not been established as an approved treatment. The program has one completed Phase 1 trial, and no trials are currently active.
Thalidomide Celgene has been studied in one completed Phase 1 trial, NCT01937442, titled Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma. The trial enrolled 7 participants across France and the United Kingdom, was uncontrolled, and was not randomized or double blinded.